Khungar Vandana, Han Steven-Huy
Curr Hepat Rep. 2010 May;9(2):75-90. doi: 10.1007/s11901-010-0039-1. Epub 2010 Apr 21.
Although nucleosides and nucleotides have a good safety record for the treatment of hepatitis B, there have been no systematic reviews on this topic. We searched Medline to include studies of the oral antiviral agents for hepatitis B and adverse events, with at least 48 weeks of follow-up from the initiation of treatment with the drug. Important toxicities include nephrotoxicity, myopathy, and resistance. It is often difficult to ascertain whether an adverse effect is from the study drug or the natural progression of the disease. Further safety data are needed for the newer agents and for all agents with regard to patients with decompensated liver disease, renal dysfunction, the elderly, children, and pregnant women.
尽管核苷和核苷酸在治疗乙型肝炎方面有良好的安全记录，但尚未有关于该主题的系统评价。我们检索了Medline，纳入了关于口服抗乙型肝炎病毒药物及其不良事件的研究，这些研究从开始用药起至少有48周的随访。重要的毒性包括肾毒性、肌病和耐药性。通常很难确定不良反应是来自研究药物还是疾病的自然进展。对于新型药物以及所有药物，在失代偿性肝病患者、肾功能不全患者、老年人、儿童和孕妇方面，还需要更多的安全性数据。
